Revisiting liver disease progression in HIV/HCV-coinfected patients: The influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3

Liver International

Volumn 35, Issue 3, 2015, Pages 876-885

  Mandorfer, Mattias ^a,b   Payer, Berit A ^a,b   Schwabl, Philipp ^a,b   Steiner, Sebastian ^a,b   Ferlitsch, Arnulf ^a,b   Aichelburg, Maximilian C ^b,c   Stättermayer, Albert F ^a   Ferenci, Peter ^a   Obermayer Pietsch, Barbara ^d   Grabmeier Pfistershammer, Katharina ^b,c   Trauner, Michael ^a,b   Peck Radosavljevic, Markus ^a,b   Reiberger, Thomas ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vienna HIV and Liver Study Group   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Chronic hepatitis C; Cirrhosis; Human immunodeficiency virus; Liver fibrosis; Portal hypertension

Indexed keywords

25 HYDROXYVITAMIN D; CD4 ANTIGEN; VITAMIN D; 25-HYDROXYVITAMIN D; ADIPONUTRIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IL28B GENE; IMMUNE STATUS; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER FIBROSIS PROGRESSION RATE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PNPLA3 GENE; PORTAL VEIN BLOOD PRESSURE; PREVALENCE; SCORING SYSTEM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC HEPATITIS C; COMPLICATION; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; COINFECTION; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; INTERLEUKINS; LIPASE; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PORTAL PRESSURE; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84922712746     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12615     Document Type: Article

References (64)

1. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-48.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl): S6-9.
3. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
4. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21, 21.e1-6.
6. Ferenci P, Ferenci S, Datz C, et al. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol 2007; 47: 31-6.
7. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44(1 Suppl): S19-24.
8. + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17: 400-9.
9. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-91.
10. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-63.
11. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370-8.
12. Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? Gastroenterology 2012; 142: 1288-92.
13. Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-80.
14. Hull MW, Rollet K, Moodie EE, et al. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS 2012; 26: 1789-94.
15. Abramovitch S, Dahan-Bachar L, Sharvit E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011; 60: 1728-37.
16. Potter JJ, Liu X, Koteish A, Mezey E. 1, 25-dihydroxyvitamin D3 and its nuclear receptor repress human alpha1 (I) collagen expression and type I collagen formation. Liver Int 2013; 33: 677-86.
17. Ding N, Yu RT, Subramaniam N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013; 153: 601-13.
18. Guzman-Fulgencio M, Garcia-Alvarez M, Berenguer J, et al. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. J Infect 2014; 68: 176-84.
19. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756-61.
20. Mandorfer M, Reiberger T, Payer BA, et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. AIDS 2013; 27: 227-32.
21. Branch AD, Kang M, Hollabaugh K, et al. In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. Am J Clin Nutr 2013; 98: 423-9.
22. Baur K, Mertens JC, Schmitt J, et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int 2012; 32: 635-43.
23. Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective associations of vitamin D with beta-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes 2011; 60: 2947-53.
24. Moreno-Perez O, Portilla J, Escoin C, et al. Impact of vitamin D insufficiency on insulin homeostasis and beta cell function in nondiabetic male HIV-infected patients. HIV Med 2013; 14: 540-8.
25. Dasarathy J, Periyalwar P, Allampati S, et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int 2014; 34: e118-27.
26. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
27. Stattermayer AF, Rutter K, Beinhardt S, et al. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. Liver Int 2014; 34: 388-95.
28. Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-9.
29. Trepo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-9.
30. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.
31. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58: 2616-23.
32. Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-17.
33. Macias J, Berenguer J, Japon MA, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56: 1261-70.
34. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192: 1943-9.
35. Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384-94.
36. Noureddin M, Wright EC, Alter HJ, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 1548-57.
37. Guzman-Fulgencio M, Berenguer J, Garcia-Alvarez M, et al. IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. J Infect 2013; 66: 170-8.
38. Petta S, Grimaudo S, Camma C, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 56: 1356-62.
39. Petta S, Rosso C, Leung R, et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 311-7.e1.
40. Stattermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57: 492-8.
41. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-8.
42. Perez-Latorre L, Sanchez-Conde M, Rincon D, et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. Clin Infect Dis 2014; 58: 713-8.
43. + cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients. J Infect Dis 2011; 203: 1802-6.
44. Ross AC, Taylor CL, Yaktine AL, Del Valle HB. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press (US), 2011.
45. Holick M F, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30.
46. Vachon ML, Factor SH, Branch AD, et al. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 2011; 54: 41-7.
47. Mandorfer M, Reiberger T, Payer BA, et al. Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. J Viral Hepat 2014; 21: 33-41.
48. Mandorfer M, Neukam K, Rivero A, et al. Strategies for assignment of HIV/HCV genotype 1-coinfected patients to either dual-therapy or direct-acting antiviral agent based triple therapy. Antivir Ther 2014; 19: 407-14.
49. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
50. Payer BA, Reiberger T, Aberle J, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012; 42: 599-606.
51. Reiberger T, Payer BA, Ferlitsch A, et al. A prospective evaluation of pulmonary, systemic and hepatic hemodynamics in HIV-HCV coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 2012; 17: 1327-34.
52. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol 2007; (20 Suppl. 1): S3-14.
53. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
54. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
55. Reiberger T, Payer BA, Ferlitsch A, et al. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 2012; 17: 1327-34.
56. Hull MW, Rollet K, Odueyungbo A, et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54: 1798-805.
57. + cell percentage in HIV/hepatitis C virus-coinfected patients. Clin Infect Dis 2013; 56: 904-5.
58. Battegay M, Mulcahy F, Geretti AM, et al. European AIDS Clinical Society (EACS) Guidelines. Version 7.0. Brussels, Belgium: European AIDS Clinical Society (EACS), 2013.
59. Loko MA, Castera L, Dabis F, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008; 103: 1973-80.
60. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17: 280-6.
61. Castera L, Winnock M, Pambrun E, et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med 2014; 15: 30-9.
62. Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012; 57: 897-909.
63. Mandorfer M, Neukam K, Reiberger T, et al. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. AIDS 2013; 27: 2707-14.
64. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.